## CORRECTION

# Correction: Impact of baseline body composition on prognostic outcomes in urological malignancies treated with immunotherapy: a pooled analysis of 10 retrospective studies

Wangbin Ma[1,2,3†], Qiao Shi[1,2,3†], Lilong Zhang[1,2,3], Zhendong Qiu[1,2,3], Tianrui Kuang[1,2,3], Kailiang Zhao[1,3*] and Weixing Wang[1,2,3*]

**Correction: BMC Cancer 24, 830 (2024)**
**https://doi.org/10.1186/s12885-024-12579-x**

Following publication of the original article [1], a typesetting error was reported. The initials of author Kailiang Zhao (ZK) were erroneously added to the author group. This has been removed in this correction article.

Further to this, the authors reported an error in Table 1, whereby the last row in the table was omitted.

---

†Wangbin Ma and Qiao Shi contributed equally to this work and are joint first authors.

The original article can be found online at https://doi.org/10.1186/s12885-024-12579-x.

*Correspondence:
Kailiang Zhao
zhaokl1983@whu.edu.cn
Weixing Wang
wangwx@whu.edu.cn
¹ Department of General Surgery, Renmin Hospital of Wuhan University,
Wuhan, China
² Hubei Key Laboratory of Digestive System Disease, Wuhan, China
³ Laboratory of General Surgery, Renmin Hospital of Wuhan University,
Wuhan, China

**BMC**

Ma et al. BMC Cancer (2024) 24:844

Page 2 of 4

The incorrect Table 1:

**Table 1** Main characteristics of the studies included

| Study | Study design | Study region | Study period | Sample size | Age | Male/female | Site | Treatment line | Treatment | Follow-up (months) | Body Composition Variables | Outcomes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aslan et al. 2022 [19] | R | Turkey | 10/2010-10/2021 | 52 | 30/22[d] | 38/14 | RCC | II | Nivolumab | 11.4 (0.7–63)[a] | SAI | OS, PFS |
| Fukata et al. 2022 [20] | R | Japan | 02/2018-03/2021, | 44 | 70 (54–80)[a] | 30/14 | UC | II | Pembrolizumab | 13.2(1–40.8)[a] | SMI | PFS |
| Ged et al. 2022 [21] | R | USA | 07/2011-04/2020 | 205 | 63 (40–90)[a] | 152/53 | RCC | I/II | ICIs | 31.2 (1–77.8)[a] | SMI, VAI, SAI | OS |
| Herrmann et al. 2022 [22] | R | France | 2016–2020 | 46 | 66 (37–86)[a] | 31/13 | RCC | II | Nivolumab | 16[c] | SMI | OS |
| Ueki et al. 2022 [23] | R | Japan | 12/2016-10/2020 | 96 | 65/31[e] | 71/25 | RCC | II | Nivolumab | 9.7 (0.3–48.4)[a] | PMI, SMI | OS, PFS |
| Martini et al. 2021(RCC) [24] | R | USA | 2015–2020 | 79 | 61.0[c] | 58/21 | RCC | I/II | ICIs | - | SMI, VAI, SAI, IAI | OS, PFS |
| Martini et al. 2021(UC) [25] | R | USA | 2015–2020 | 70 | 69.5[c] | 49/21 | UC | I/II | ICIs | 20.1[c] | SMI, VAI, SAI, IFI | OS, PFS |
| Fukushima et al. 2020 [26] | R | Japan | 01/2018-02/2020 | 28 | 74 (70–82)[b] | 19/9 | UC | II | Pembrolizumab | 6 (3–18)[b] | SMI | OS, PFS |
| Shimizu et al. 2020 [27] | R | Japan | 12/2017-08/2019 | 27 | 73 (52–82)[a] | 23/4 | UC | II | Pembrolizumab | 7 (1–20)[a] | PMI | OS, PFS |

[a] medians with ranges; [b] median and interquartile range; [c] medians; [d] < 65/ ≥ 65; [e] < 75/ ≥ 75; R, retrospective study; UC, urothelial carcinoma; RCC, renal cell carcinoma; SMI, skeletal muscle index; PMI, psoas muscle index; VAI, visceral adiposity index; SAI, subcutaneous adiposity index; IAI, inter-muscular adiposity index; OS, overall survival; PFS, progression-free survival; ICI, immune checkpoint inhibitor

Ma *et al. BMC Cancer*     (2024) 24:844

Page 3 of 4

The corrected Table 1:

**Table 1** Main characteristics of the studies included

| Study | Study design | Study region | Study period | Sample size | Age | Male/female | Site | Treatment line | Treatment | Follow-up (months) | Body Composition Variables | Outcomes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aslan et al. 2022 [19] | R | Turkey | 10/2010-10/2021 | 52 | 30/22[d] | 38/14 | RCC | II | Nivolumab | 11.4 (0.7–63)[a] | SAI | OS, PFS |
| Fukata et al. 2022 [20] | R | Japan | 02/2018-03/2021, | 44 | 70 (54–80)[a] | 30/14 | UC | II | Pembrolizumab | 13.2(1–40.8)[a] | SMI | PFS |
| Ged et al. 2022 [21] | R | USA | 07/2011-04/2020 | 205 | 63 (40–90)[a] | 152/53 | RCC | I/II | ICIs | 31.2 (1–77.8)[a] | SMI, VAI, SAI | OS |
| Herrmann et al. 2022 [22] | R | France | 2016–2020 | 46 | 66 (37–86)[a] | 31/13 | RCC | II | Nivolumab | 16[c] | SMI | OS |
| Ueki et al. 2022 [23] | R | Japan | 12/2016-10/2020 | 96 | 65/31[e] | 71/25 | RCC | II | Nivolumab | 9.7 (0.3–48.4)[a] | PMI, SMI | OS, PFS |
| Martini et al. 2021(RCC) [24] | R | USA | 2015–2020 | 79 | 61.0[c] | 58/21 | RCC | I/II | ICIs | - | SMI, VAI, SAI, IAI | OS, PFS |
| Martini et al. 2021(UC) [25] | R | USA | 2015–2020 | 70 | 69.5[c] | 49/21 | UC | I/II | ICIs | 20.1[c] | SMI, VAI, SAI, IFI | OS, PFS |
| Fukushima et al. 2020 [26] | R | Japan | 01/2018-02/2020 | 28 | 74 (70–82)[b] | 19/9 | UC | II | Pembrolizumab | 6 (3–18)[b] | SMI | OS, PFS |
| Shimizu et al. 2020 [27] | R | Japan | 12/2017-08/2019 | 27 | 73 (52–82)[a] | 23/4 | UC | II | Pembrolizumab | 7 (1–20)[a] | PMI | OS, PFS |
| Takei et al. 2024 [28] | R | Japan | 2019-2023 | 60 | 71 (63-75) | 46/14 | RCC | I/II | Ipilimumab+Nivolumab | 15(1–52) [a] | SMI, VAI, SAI | OS, PFS |

[a] medians with ranges; [b]median and interquartile range; [c]medians; [d] <65/≥65; [e] <75/≥75; R, retrospective study; UC, urothelial carcinoma; RCC, renal cell carcinoma; SMI, skeletal muscle index; PMI, psoas muscle index; VAI, visceral adiposity index; SAI, subcutaneous adiposity index; IAI, inter-muscular adiposity index; PFS, progression-free survival; OS, overall survival; ICI, immune checkpoint inhibitor

Ma *et al. BMC Cancer*    (2024) 24:844

Page 4 of 4

The original article [1] has been corrected.

Published online: 16 July 2024

**Reference**
1. Ma W, Shi Q, Zhang L, et al. Impact of baseline body composition on prognostic outcomes in urological malignancies treated with immunotherapy: a pooled analysis of 10 retrospective studies. BMC Cancer. 2024;24:830. https://doi.org/10.1186/s12885-024-12579-x.